Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue: 2010-2018

Historic Current Deferred Revenue for Neurocrine Biosciences (NBIX) over the last 7 years, with Mar 2018 value amounting to $731,000.

  • Neurocrine Biosciences' Current Deferred Revenue fell 79.42% to $731,000 in Q1 2018 from the same period last year, while for Mar 2018 it was $731,000, marking a year-over-year decrease of 79.42%. This contributed to the annual value of $731,000 for FY2017, which is 79.27% down from last year.
  • Per Neurocrine Biosciences' latest filing, its Current Deferred Revenue stood at $731,000 for Q1 2018, which was down 0.00% from $731,000 recorded in Q4 2017.
  • Neurocrine Biosciences' 5-year Current Deferred Revenue high stood at $10.2 million for Q4 2015, and its period low was $731,000 during Q2 2017.
  • Over the past 3 years, Neurocrine Biosciences' median Current Deferred Revenue value was $3.4 million (recorded in 2016), while the average stood at $2.3 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 206.86% in 2015, then crashed by 79.42% in 2018.
  • Neurocrine Biosciences' Current Deferred Revenue (Quarterly) stood at $3.3 million in 2014, then spiked by 206.86% to $10.2 million in 2015, then crashed by 65.43% to $3.5 million in 2016, then crashed by 79.27% to $731,000 in 2017, then slumped by 79.42% to $731,000 in 2018.
  • Its Current Deferred Revenue stands at $731,000 for Q1 2018, versus $731,000 for Q4 2017 and $731,000 for Q3 2017.